ArticleJournal of translational medicine2026
Whole exome sequencing: a new era in prenatal diagnostics.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvances in bioinformatics have revealed the potential of whole exome sequencing (WES) for copy number variations (CNVs) detection. This study aimed to evaluate whether WES can replace low pass copy number variation sequencing (CNV-seq) for the detection of CNVs in clinical prenatal diagnosis.
methodsBased on a cohort of 1055 fetuses tested concurrently with trio-WES and CNV-Seq, we performed a systematic comparison of both methods for the detection of aneuploidies, mosaicism, and pathogenic/likely pathogenic (P/LP) CNVs.
resultsBoth WES and CNV-Seq concordantly identified 11 aneuploidies, 4 mosaicism, and 29 P/LP CNVs. The aneuploidies comprised eight cases of trisomy 21, two cases of 45,X, and one case of 47,XXX. Four mosaicisms consisted of two whole-chromosome mosaicism (WCM) and two segmental aneuploid mosaicism. The two platforms demonstrated comparable accuracy in copy number (CN) detection for both aneuploidies and whole-chromosome mosaicism. However, WES showed comparatively lower precision than CNV-Seq in detecting CN alterations within segmental aneuploid mosaicism. For P/LP CNVs, both platforms demonstrated full concordance in the quantity and pathogenicity classification, although minor discrepancies were observed in their genomic locations and sizes determination. The Jaccard similarity coefficient values ranged from 57.9% to 99.7% (mean±SD, 90.2%±9.5%). Notably, only three cases fell below the 80% threshold, 1q21·1q21.2 deletion (66.0%), 1q21·1q21.2 duplication (57.9%) and 2q32·2q32.1 deletion (78.2%). After excluding these three samples, the similarity improved to 81.3%-99.7% (mean± SD, 92.7%±5.4%).
conclusionWES shows comparable detection of aneuploidies, WCM, and P/LP CNVs to CNV-Seq, supporting its use as a first-tier prenatal diagnostic approach. However, caution remains for segmental mosaicism and certain regions with reduced precision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.